Business
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:
About this update from Benitec Biopharma Inc.
[{"type":"image","alt":"Benitec Biopharma Inc.","displaySize":"","headline":null,"caption":"Benitec Biopharma Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/272fa36373841b48b583df523fcc23c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UXB1UGWRUrJF0EGvi0kT6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMw--/https://media.zenfs.com/en/globenewswire.com/272fa36373841b48b583df523fcc23c2","width":300,"height":95}},"lazy":false},{"type":"text","content":"- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient ","length":288,"tagName":"p"},{"type":"text","content":"- BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD ","length":136,"tagName":"p"},{"type":"text","content":"HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced the acceptance of the interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia for oral presentation at the 2026 American Society of Gene and Cell Therapy Annual Meeting (ASGCT). Interim clinical results for patients enrolled into Cohort 1 and Cohort 2 will be discussed in an oral presentation at ASGCT, being held in Boston, MA from May 11 – 15, 2026.","length":785,"tagName":"p"},{"type":"text","content":"Details regarding the BB-301 Oral Presentation are as follows: Session Name: Long-term safety and durable efficacy in cell and gene therapyPresentation Date and Time: 05/15/2026, 09:15 AM - 09:30 AMLocation: MCEC Room 257AB (Level 2)Abstract ID: 448Presenter: Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer, Benitec Biopharma","length":369,"tagName":"p"},{"type":"text","content":"About OPMD There are currently no approved th...